pacific biosciences of california inc. - PACB
PACB
Close Chg Chg %
2.27 -0.23 -9.91%
Closed Market
2.05
-0.23 (9.91%)
Volume: 7.14M
Last Updated:
Dec 12, 2024, 4:00 PM EDT
Company Overview: pacific biosciences of california inc. - PACB
PACB Key Data
| Open $2.25 | Day Range 2.03 - 2.29 |
| 52 Week Range 1.16 - 10.65 | Market Cap $621.67M |
| Shares Outstanding 273.86M | Public Float 241.81M |
| Beta 1.94 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.46 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 10.42M |
PACB Performance
| 1 Week | 0.74% | ||
| 1 Month | 28.21% | ||
| 3 Months | 12.98% | ||
| 1 Year | -78.34% | ||
| 5 Years | -62.95% |
PACB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
16
Full Ratings ➔
About pacific biosciences of california inc. - PACB
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
PACB At a Glance
Pacific Biosciences of California, Inc.
1305 O'Brien Drive
Menlo Park, California 94025
| Phone | 1-650-521-8000 | Revenue | 200.52M | |
| Industry | Medical Specialties | Net Income | -306,735,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 56.286% | |
| Fiscal Year-end | 12 / 2024 | Employees | 796 | |
| View SEC Filings |
PACB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.408 |
| Price to Book Ratio | 3.745 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.049 |
| Enterprise Value to Sales | 13.915 |
| Total Debt to Enterprise Value | 0.335 |
PACB Efficiency
| Revenue/Employee | 251,910.804 |
| Income Per Employee | -385,345.477 |
| Receivables Turnover | 5.476 |
| Total Asset Turnover | 0.114 |
PACB Liquidity
| Current Ratio | 7.809 |
| Quick Ratio | 7.212 |
| Cash Ratio | 6.648 |
PACB Profitability
| Gross Margin | 20.12 |
| Operating Margin | -154.779 |
| Pretax Margin | -158.666 |
| Net Margin | -152.969 |
| Return on Assets | -17.462 |
| Return on Equity | -48.526 |
| Return on Total Capital | -18.758 |
| Return on Invested Capital | -19.623 |
PACB Capital Structure
| Total Debt to Total Equity | 133.17 |
| Total Debt to Total Capital | 57.113 |
| Total Debt to Total Assets | 53.489 |
| Long-Term Debt to Equity | 131.733 |
| Long-Term Debt to Total Capital | 56.496 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Pacific Biosciences Of California Inc. - PACB
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 78.89M | 130.51M | 128.30M | 200.52M | |
Sales Growth
| -13.20% | +65.43% | -1.69% | +56.29% | |
Cost of Goods Sold (COGS) incl D&A
| 46.33M | 71.73M | 79.45M | 160.18M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 9.30M | 11.59M | 17.32M | 32.69M | |
Depreciation
| 9.30M | 11.20M | 16.41M | 18.27M | |
Amortization of Intangibles
| - | 381.00K | 913.00K | 14.42M | |
COGS Growth
| -17.74% | +54.83% | +10.76% | +101.61% | |
Gross Income
| 32.57M | 58.78M | 48.85M | 40.34M | |
Gross Income Growth
| -5.81% | +80.51% | -16.89% | -17.42% | |
Gross Profit Margin
| +41.28% | +45.04% | +38.08% | +20.12% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 136.95M | 236.95M | 353.67M | 350.71M | |
Research & Development
| 64.15M | 112.90M | 193.00M | 187.17M | |
Other SG&A
| 72.80M | 124.05M | 160.67M | 163.54M | |
SGA Growth
| +1.35% | +73.02% | +49.26% | -0.84% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (98.00M) | 32.27M | 2.38M | 26.14M | |
EBIT after Unusual Expense
| (6.39M) | (210.44M) | (307.20M) | (336.50M) | |
Non Operating Income/Expense
| 36.05M | (51.91M) | 7.64M | 32.68M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 267.00K | 12.53M | 14.69M | 14.34M | |
Interest Expense Growth
| -89.77% | +4,592.88% | +17.24% | -2.36% | |
Gross Interest Expense
| 267.00K | 12.53M | 14.69M | 14.34M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 29.40M | (274.87M) | (314.25M) | (318.16M) | |
Pretax Income Growth
| +134.95% | -1,034.84% | -14.33% | -1.24% | |
Pretax Margin
| +37.27% | -210.61% | -244.92% | -158.67% | |
Income Tax
| - | - | (93.65M) | (11.42M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | (11.42M) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 29.40M | (181.22M) | (314.25M) | (306.74M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 29.40M | (181.22M) | (314.25M) | (306.74M) | |
Net Income Growth
| +134.95% | -716.34% | -73.40% | +2.39% | |
Net Margin Growth
| +37.27% | -138.85% | -244.92% | -152.97% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 29.40M | (181.22M) | (314.25M) | (306.74M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 29.40M | (181.22M) | (314.25M) | (306.74M) | |
EPS (Basic)
| 0.178 | -0.8878 | -1.3995 | -1.2094 | |
EPS (Basic) Growth
| +132.27% | -598.76% | -57.64% | +13.58% | |
Basic Shares Outstanding
| 165.19M | 204.14M | 224.55M | 253.63M | |
EPS (Diluted)
| 0.168 | -0.8878 | -1.3995 | -1.2094 | |
EPS (Diluted) Growth
| +130.46% | -628.45% | -57.64% | +13.58% | |
Diluted Shares Outstanding
| 174.97M | 204.14M | 224.55M | 253.63M | |
EBITDA
| (95.08M) | (166.58M) | (287.50M) | (277.67M) | |
EBITDA Growth
| -4.95% | -75.20% | -72.59% | +3.42% | |
EBITDA Margin
| -120.52% | -127.63% | -224.08% | -138.48% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 2.917 | |
| Number of Ratings | 16 | Current Quarters Estimate | -0.205 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.361 | |
| Last Quarter’s Earnings | -0.22 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.21 | Next Fiscal Year Estimate | -0.675 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 10 | 9 | 14 |
| Mean Estimate | -0.20 | -0.18 | -1.36 | -0.68 |
| High Estimates | -0.16 | -0.13 | -1.31 | -0.53 |
| Low Estimate | -0.29 | -0.23 | -1.43 | -0.85 |
| Coefficient of Variance | -19.86 | -15.85 | -3.13 | -15.54 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 9 | 9 | 8 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Pacific Biosciences Of California Inc. - PACB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Pacific Biosciences Of California Inc. - PACB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 21, 2024 | Bill Ericson Director | 41,616 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Hannah A. Valantine Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Hannah A. Valantine Director | 22,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | David W. Meline Director | 24,134 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | David W. Meline Director | 57,116 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Kathy P. Ordoñez Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Kathy P. Ordoñez Director | 403,037 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Bill Ericson Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | John F. Milligan Director | 132,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Lucy Shapiro Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Lucy Shapiro Director | 22,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Randall S. Livingston Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Randall S. Livingston Director | 22,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Marshall L. Mohr Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Marshall L. Mohr Director | 132,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | John F. Milligan Director | 32,179 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 23, 2024 | Michele Farmer See Remarks | 211,941 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.03 per share | 430,240.23 |
| Mar 20, 2024 | Kathy P. Ordoñez Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 20, 2024 | Kathy P. Ordoñez Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 7, 2024 | Christian O. Henry See Remarks | 2,596,670 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.87 per share | 12,645,782.90 |